Arch Endocrinol Metab. 2018 Feb;62(1):106-124. doi: 10.20945/2359-3997000000015.

Diagnosis and treatment [ ... ]

J Obes. 2018 May 3;2018:3251675. doi: 10.1155/2018/3251675. eCollection 2018.
Is There Association between [ ... ]

Objective: As Selumetinib is a MEK1/2 inhibitor that has gained interest as an anti-tumor agent, [ ... ]